Genelux Corporation (GNLX) News

GNLX EXIT AT WEEKLY ROAD BLOCK

GNLX.........................https://stockcharts.com/h-sc/ui?s=GNLX&p=W&b=5&g=0&id=p86431144783

GNLX MONSTER READY TO BREAK OUT

$GNLX Could Genelux's Olvi-Vec Emerge As A Powerful Tool In The Fight Against Difficult-to-treat Cancers?
Shares of Genelux Corp. (GNLX) have lost over 70% from their 52-week high of $12.12, recorded last January, and trade around $3.15.

This late clinical-stage biopharmaceutical company is developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumors. Its lead drug candidate is Olvi-Vec, a modified form of the oncolytic vaccinia virus.

Oncolytic immunotherapy refers to the treatment of cancer with viruses that selectively replicate in tumors and kill the cancer cells while leaving the normal cells untouched.

Olvi-Vec via intraperitoneal infusion is being evaluated in a phase III trial in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer, dubbed OnPrime. In this trial, the efficacy and safety of Olvi-Vec, platinum-doublet chemotherapy, and bevacizumab (Avastin) are compared with platinum-doublet chemotherapy plus bevacizumab.

Ovarian cancer is the second most common gynecologic cancer in the United States. Platinum-based chemotherapy treatments have proven effective for some individuals with cancer. However, if the cancer recurs following platinum treatment, it is classified as platinum-resistant. For patients with platinum-resistant ovarian cancer (PROC), treatment options are severely limited, and the prognosis for survival is generally poor.

Initiated in 2022, the OnPrime study is designed to enroll 186 women with platinum-resistant/refractory ovarian cancer and is being conducted as a collaboration between Genelux and The Gynecological Oncological Group (GOG).

The primary endpoint of the study is progression-free survival (PFS) based on *RECIST 1.1, as assessed by a blinded independent central review. Key secondary endpoints include overall response rate (ORR), overall survival (OS), and safety. (*RECIST 1.1, the most current version of the Response Evaluation Criteria in Solid Tumors, is a standardized set of criteria used to objectively measure tumor burden and assess the response to treatment in oncology clinical trials).

The OnPrime study continues to enroll patients, and topline results are expected in the second half of 2025.

Read more https://www.rttnews.com/3505338/could-genelux-s-olvi-vec-emerge-as-a-powerful-tool-in-the-fight-against-difficult-to-treat-cancers.aspx

$GNLX Genelux_Corp Corporation to Participate in a Fireside Chat with H.C. Wainwright
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.



https://finance.yahoo.com/news/genelux-corporation-participate-fireside-chat-120100563.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

$GNLX November 2024 Corporate Presentation

https://investors.genelux.com/static-files/cb26a67f-274b-49ab-84cc-de52b67c4118

$GNLX NASDAQ Genelux 2024 Annual Stockholder Meeting

https://finviz.com/quote.ashx?t=GNLX&ty=c&ta=1&p=d

Any news for pop??
Found it….sorry, just saw


Genelux Corporation Announces
First Patient Dosed in Phase 2
Trial Evaluating Systemic
Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
GlobeNewswire
- VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-
doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer-
- Trial represents second indication in the clinic for Olvi-Vec via systemic administration -
- Interim readout expected mid-2025 -
WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) - Genelux Corporation (GNLX. NaE) , a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies.

$GNLX Trending up resistance in play https://schrts.co/nQTnXUut

$GNLX On alert for News!? stay tuned..

$GNLX Possible Breakout! announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.

https://finance.yahoo.com/news/genelux-corporation-present-h-c-200100800.html

$GNLX 1 Month chart resistance in play https://schrts.co/BWBNmgEe

$GNLX Fundamental breakout Volume recovery get in early for the big boom https://schrts.co/sGWIJqyY

GNLX under $3

Is Genelux (NASDAQ: $GNLX) In A Good Position To Invest In Growth? https://finance.yahoo.com/news/genelux-nasdaq-gnlx-good-position-134334395.html

$GNLX Technical chart
https://schrts.co/SjVYghqR

$GNLX Website : https://genelux.com/

GNLX under $3

$GNLX historical movement price and volume https://ih.advfn.com/stock-market/NASDAQ/genelux-GNLX/historical

GNLX new 52 week low

GNLX new 52 lo

GNLX new 52 lo

GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer
Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor

https://stockcharts.com/h-sc/ui?s=GNLX

Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.

The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.